Cardiovascular Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Titan Pharmaceuticals

Biopharmaceutical company reports third quarter 2004 results

Net loss for the third quarter of 2004 was approximately $6.3 million, or $0.20 per share, compared to a net loss of approximately $6.2 million, or $0.22 per share, for the same period last year.

For the first 9 months of 2004, net loss was approximately $18.2 million, or $0.59 per share, compared to approximately $19.4 million, or $0.70 per share, for the same 9-month period in 2003.

Research and development (R&D) expenses for third quarter 2004 were approximately $4.9 million, compared to $5.3 million for the same...

• View Other Issues of Cardiovascular Business Week
  
• View Other NewsRx Publications